Review of ophthalmic drug delivery by contact lenses

被引:87
作者
Hsu, K-H. [1 ]
Gause, S. [1 ]
Chauhan, A. [1 ]
机构
[1] Univ Florida, Dept Chem Engn, Gainesville, FL 32611 USA
基金
美国国家科学基金会;
关键词
Contact lenses; Ophthalmic drug delivery; Vitamin E barriers; Microparticles; Imprinting; Glaucoma; MOLECULARLY IMPRINTED POLYMERS; OCULAR TEAR FLOW; SILICONE-HYDROGEL; EXTENDED DELIVERY; CONTROLLED-RELEASE; CIPROFLOXACIN-HCL; HYDROPHILIC LENS; ACUTE GLAUCOMA; HEMA HYDROGEL; SYSTEMS;
D O I
10.1016/S1773-2247(14)50021-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Ophthalmic drugs are almost exclusively delivered through eye drops in spite of several deficiencies including low bioavailability and poor compliance. Contact lenses are ideally suited for delivery of drugs to the anterior chamber because of the placement directly on the cornea which results in a high bioavailability of at least 50 % compared to about 1-5 % for eye drops. The ten-fold increase in bioavailability reduces the amount of drug delivered, which in turn reduces the systemic loss of the drug, thereby reducing the potential for side effects. Additionally contact lenses can provide a most uniform release profile compared to the pulsatile delivery with eye drops, which can potentially result in improved therapeutic outcomes. Finally drug delivery via extended wear contact lenses can significantly improve the compliance. In spite of all these benefits, contact lenses are not yet available as drug delivery vehicles mainly because the earlier lens designs were not optimized for drug delivery. The interest in developing contact lenses for drug delivery has significantly increased in the last decade as several new techniques have been developed for designing contact lenses for extended drug delivery. The latest studies show that contact lenses can achieve extended release of a few weeks without any significant impact on critical lens properties. Also in vivo animal studies have proven safety, efficacy and increased bioavailability compared to eye drops. The future appears promising for drug eluting contact lenses but several challenges remain to be overcome regarding processing and storage issues, lack of use in the elderly population. regulatory issues, high costs of clinical studies and cost-benefit analysis.
引用
收藏
页码:123 / 135
页数:13
相关论文
共 107 条
  • [1] Achouri D., DRUG DEV IND PHARM, P1
  • [2] Al-Kinani A.A., 2012, Patenting Nanomedicines, P277, DOI DOI 10.1007/978-3-642-29265-1_9
  • [3] Controlled Release of High Molecular Weight Hyaluronic Acid from Molecularly Imprinted Hydrogel Contact Lenses
    Ali, Maryam
    Byrne, Mark E.
    [J]. PHARMACEUTICAL RESEARCH, 2009, 26 (03) : 714 - 726
  • [4] Zero-order therapeutic release from imprinted hydrogel contact lenses within in vitro physiological ocular tear flow
    Ali, Maryarn
    Horikawa, Shin
    Venkatesh, Siddarth
    Saha, Jishnu
    Hong, Jong Wook
    Byrne, Mark E.
    [J]. JOURNAL OF CONTROLLED RELEASE, 2007, 124 (03) : 154 - 162
  • [5] Molecularly imprinted polymers for drug delivery
    Alvarez-Lorenzo, C
    Concheiro, A
    [J]. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2004, 804 (01): : 231 - 245
  • [6] Soft contact lenses capable of sustained delivery of timolol
    Alvarez-Lorenzo, C
    Hiratani, H
    Gómez-Amoza, JL
    Martínez-Pacheco, R
    Souto, C
    Concheiro, A
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2002, 91 (10) : 2182 - 2192
  • [7] Alvarez-Lorenzo C., 2006, AM J DRUG DELIV, V4, P131, DOI [DOI 10.2165/00137696-200604030-00002, 10.2165/00137696-200604030-00002]
  • [8] Imprinted soft contact lenses as norfloxacin delivery systems
    Alvarez-Lorenzo, Carmen
    Yanez, Fernando
    Barreiro-Iglesias, Rafael
    Concheiro, Angel
    [J]. JOURNAL OF CONTROLLED RELEASE, 2006, 113 (03) : 236 - 244
  • [9] Improving the loading and release of NSAIDs from pHEMA hydrogels by copolymerization with functionalized monomers
    Andrade-Vivero, Paula
    Fernandez-Gabriel, Elena
    Alvarez-Lorenzo, Carmen
    Concheiro, Angel
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2007, 96 (04) : 802 - 813
  • [10] Bartlett JD., 2005, Ophthalmic Drug Facts, P93